SCHEMBL20545868

SCHEMBL20545868

COC(=O)c1sccc1N(C)C(C)=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
NPC1 O15118 1/20 0.47
MEN1 O00255 2/20 0.46
CYP1A2 P05177 1/20 0.46
HPGD P15428 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPK10 P53779 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
POLB P06746 2/20 0.42
PKM P14618 1/20 0.42
ATM Q13315 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3571523 0.81 KMT2A (0.44) KMT2ANPC1MEN1CYP1A2HPGD
SCHEMBL22261640 0.80 NPC1 (0.46) KMT2ANPC1MEN1CYP1A2HPGD
SCHEMBL2493883 0.77 KMT2A (0.51) KMT2ANPC1MEN1CYP1A2HPGD
SCHEMBL7370311 0.77 L3MBTL1 (0.43) KMT2ANPC1MEN1CYP1A2HPGD
SCHEMBL6285884 0.77 KMT2A (0.56) KMT2ANPC1MEN1CYP1A2HPGD
SCHEMBL7373545 0.73 KMT2A (0.50) KMT2ANPC1MEN1HPGDSMN1; SMN2
SCHEMBL2654173 0.73 KMT2A (0.54) KMT2ANPC1MEN1CYP1A2HPGD
SCHEMBL16866359 0.73 KMT2A (0.53) KMT2ANPC1MEN1CYP1A2HPGD
SCHEMBL375957 0.72 KMT2A (0.56) KMT2ANPC1MEN1CYP1A2HPGD
SCHEMBL70575 0.72 KMT2A (0.56) KMT2ANPC1MEN1CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 EP disclosed
CN-110914242-B Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2023-07-25 CN disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 US disclosed
CN-110914242-A Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2020-03-24 CN disclosed
EP-3615514-A2 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF Aviara Pharmaceuticals, Inc. (US) 2020-03-04 EP disclosed
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof AVIARA PHARMACEUTICALS, INC. (US) 2018-11-01 US disclosed
WO-2018201167-A2 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS, INC. (US) 2018-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof ITGB3, ITGA1, ITGB5 KMT2A 4455/4885NPC1 3297/4885MEN1 2419/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 KMT2A 4455/4885NPC1 3297/4885MEN1 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.